While clearance of CYP3A4 substrates is lower in patients with obesity, drugs primarily metabolized by UGT, xanthine oxidase, N-acetyltransferase, or CYP2E1 exhibit higher clearance in individuals with obesity [14–17]. Here, CYP3A4 is linked to obesity disorder.